EGFR and colorectal adenocarcinoma: Of note, EGFR clustering was reduced by LDL-DHA and BSA-DHA treatment in SW48 colorectal adenocarcinoma cells (supplemental Fig. S6), which express high levels of EGFR (59) containing a G719S mutation, which is constitutively active and resistant to kinase inhibitors (60, 61).